Core Viewpoint - Cue Biopharma, Inc. has reported its fourth quarter and full year 2024 financial results, highlighting progress in its autoimmune programs and the strategic focus on its Immuno-STAT™ platform, particularly CUE-401 [1][2]. Financial Results Summary Fourth Quarter 2024 - Collaboration revenue decreased to $1.6 million from $1.8 million in Q4 2023, attributed to a prior strategic collaboration with Ono Pharmaceutical [2]. - Research and development expenses were $7.2 million, down from $10.9 million in Q4 2023, mainly due to reduced drug substance manufacturing and clinical trial costs [3]. - General and administrative expenses decreased to $4.0 million from $4.6 million in Q4 2023, primarily due to lower professional fees [3]. Full Year 2024 - Collaboration revenue increased to $9.3 million from $5.5 million in 2023, driven by the strategic collaboration with Ono Pharmaceutical [4]. - Research and development expenses totaled $36.3 million, down from $40.8 million in 2023, due to decreases in clinical trial costs and employee compensation [5]. - General and administrative expenses were $14.6 million, reduced from $16.7 million in 2023, mainly due to lower employee compensation and professional fees [6]. - As of December 31, 2024, the company had $22.5 million in cash and cash equivalents [6]. Strategic Developments - The company is prioritizing resources on autoimmune programs while advancing clinical data from oncology programs to support strategic partnerships [8]. - Key industry leaders have been appointed to the management team, enhancing expertise in strategic transactions and drug development [8]. - The company has regained worldwide development and commercialization rights for CUE-401, its lead autoimmune program, which has the potential to transform treatment for various autoimmune and inflammatory diseases [8].